Put the Missing Piece in Place

In a 6-month study, 63% (27/43) of adults treated with GATTEX reduced their weekly volume of PS by ≥20% or more vs 30% with placebo (13/43) at Weeks 20 and 24. P=0.002, the primary endpoint. In the same study, adult patients treated with GATTEX achieved a reduction of ≥1 day off PS per week (21/39) vs placebo (9/39), an exploratory endpoint. In the 24-month open-label extension, adult patients previously treated with GATTEX weaned off PS completely after 30 months of treatment (10/30).¹

In a 6-month study, pediatric patients treated with GATTEX reduced weekly PS volume by ≥20% (18/26), the primary endpoint. They also achieved a reduction of ≥1 day off PS per week (10/26)—mean PS infusion time at baseline was 7 days/week—and patients weaned off PS completely (3/26), secondary endpoints.¹